Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study

(“Type 2 Diabetes Mellitus Duration and Obesity Alter the Efficacy of Autologously Transplanted Bone Marrow-derived Mesenchymal Stem/Stromal Cells”) published in Stem Cells Translational Medicine.

 

 In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients’ own bodies.

 

A total of 30 adult patients with different body mass indexes whose Type 2 diabetes histories varied from one to 25 years were recruited for the study. Each received two infusions of the cells intravenously or by injection into an artery that supplies blood to the pancreas.

 

Researchers monitored the patients for 48 hours and re-examined them at one-month, three-month, six-month, and one-year intervals. No significant problems were detected in the patients’ health as a result of the treatment, and they appeared to benefit equally from both infusion methods.

 

“Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM), but the results of autologous BM-MSC administration in T2DM patients are contradictory. The purpose of this study was to test the hypothesis that autologous BM-MSC administration in T2DM patient is safe, and that the efficacy of the treatment is dependent on the quality of the autologous BM-MSC population and administration routes,” write the investigators.

 

”T2DM patients were enrolled, randomly assigned (1:1) by a computer-based system into the intravenous and dorsal pancreatic arterial groups. The safety was assessed in all the treated patients, and the efficacy was evaluated based on the absolute changes in the hemoglobin A1c, fasting blood glucose, and C-peptide levels throughout the 12-month follow-up. Our data indicated that autologous BM-MSC administration was well tolerated in 30 T2DM patients. Short-term therapeutic effects were observed in patients with T2DM duration of less 10 years and a body mass index less 23, which is in line with the phenotypic analysis of the autologous BM-MSC population. T2DM duration directly altered the proliferation rate of BM-MSCs, abrogated the glycolysis and mitochondria respiration of BM-MSCs, and induced the accumulation of mitochondria DNA mutation.

 

“Our data suggest that autologous administration of BM-MSCs in the treatment of T2DM should be performed in patients with T2DM duration less 10 years and no obesity. Prior to further confirming the effects of T2DM on BM-MSC biology, future work with a larger cohort focusing on patients with different T2DM history is needed to understand the mechanism underlying our observation.”

 

“Our patients tolerated the procedure well and showed short-term reductions in their blood glucose levels after the treatment,” said Liem Nguyen, MD, PhD, the institute’s research director. “We also found that some of them were able to temporarily reduce the dosage of their diabetes medications.”

 

Some 420 million people worldwide have Type 2 diabetes, a disorder accounting for about 90 percent of all diabetes cases that often leads to disability or death. People with Type 2 diabetes cannot make good use of the insulin their bodies produce. Increased physical activity and a healthy diet can improve the disorder in some people, but many must take insulin or drugs to control their blood glucose levels.

 

Patients in the Vinmec study were classified into three groups based on the diabetes medicines they were regularly taking before their stem cell infusions. Some were maintaining their blood glucose levels with insulin only. Others were taking drugs but no insulin, and still others were taking a combination of insulin and drugs.

 

After receiving the treatment, more than half of the patients were able to lower the doses of their diabetes medicines.

 

“Our trial, the first to link the outcomes of autologous bone marrow stromal stem cell transplantation with body mass index and Type 2 diabetes duration, shows the procedure is safe and opens the way for other clinical trials exploring the potential benefits of this treatment in non-obese patients who have had the disorder less than 10 years,” Nguyen said.

 

Bone marrow stromal stem cells, also known as mesenchymal stem cells, play a key role in the body’s immune response and can transform into connective tissue cells in any organ. Over the past 50 years, they have emerged as a versatile cell source in the field of regenerative medicine.

 

“The results of this randomized clinical trial for patients with Type 2 diabetes and the injection of their own bone marrow stromal stem cells is encouraging and potentially may add to the treatment arsenal for this chronic disease that affects so many worldwide,” said Anthony Atala, MD, Editor-in-Chief of Stem Cells Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “Of special interest is the short-term efficacy in patients with a history of Type 2 diabetes for less than 10 years and a bone mass index of less than 23. This work opens opportunities for future research to further investigate this area of work.”

 

Source: Type 2 Diabetes Patients Can Benefit from Stem Cell Transplants (genengnews.com)